It is important to note that MTX should still remain the treatment of choice for certain groups of women, such as those who have a contraindication to radiation therapy, e.g., women with certain connective tissue disorders, pregnancy, certain hereditary gene mutations such as BRCA1 and BRCA2 or where large tumour to breast ratio makes BCS + RT impractical [2,37]. Here, BRCA1 is linked to connective tissue disorder.